ResMed (NYSE:RMD) Price Target Lowered to $225.00 at Piper Sandler

ResMed (NYSE:RMD) had its price target decreased by Piper Sandler from $233.00 to $225.00 in a report issued on Friday,Benzinga reports. Piper Sandler currently has a neutral rating on the medical equipment provider’s stock.

A number of other brokerages have also weighed in on RMD. Royal Bank Of Canada lowered ResMed from an “outperform” rating to a “sector perform” rating and set a $234.00 price target on the stock. in a research note on Thursday, July 16th. Robert W. Baird set a $213.00 price objective on ResMed in a research report on Friday. KeyCorp dropped their target price on ResMed from $260.00 to $255.00 and set an “overweight” rating for the company in a research note on Friday. Evercore set a $255.00 target price on ResMed and gave the stock an “outperform” rating in a research report on Monday, April 13th. Finally, Jefferies Financial Group decreased their price target on ResMed from $240.00 to $225.00 and set a “hold” rating on the stock in a research note on Friday, July 10th. Seven research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat.com, ResMed presently has a consensus rating of “Hold” and an average price target of $240.17.

ResMed Stock Performance

NYSE:RMD opened at $211.84 on Friday. The firm has a 50 day simple moving average of $200.49 and a 200-day simple moving average of $222.23. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.01 and a quick ratio of 2.33. The firm has a market cap of $30.73 billion, a PE ratio of 20.31, a P/E/G ratio of 1.36 and a beta of 0.76. ResMed has a 1-year low of $180.26 and a 1-year high of $293.81.

ResMed (NYSE:RMD) last announced its earnings results on Thursday, August 6th. The medical equipment provider reported $2.95 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.89 by $0.06. The firm had revenue of $1.46 billion for the quarter, compared to analyst estimates of $1.46 billion. ResMed had a net margin of 26.94% and a return on equity of 25.86%. ResMed’s revenue was up 8.6% compared to the same quarter last year. During the same quarter last year, the business earned $2.55 earnings per share. On average, equities analysts expect that ResMed will post 12.02 EPS for the current year.

ResMed Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 24th. Stockholders of record on Thursday, August 20th will be paid a dividend of $0.66 per share. The ex-dividend date of this dividend is Thursday, August 20th. This represents a $2.64 annualized dividend and a dividend yield of 1.2%. This is a boost from ResMed’s previous quarterly dividend of $0.60. ResMed’s dividend payout ratio is presently 23.14%.

Insiders Place Their Bets

In other news, CEO Michael J. Farrell sold 4,991 shares of the company’s stock in a transaction on Tuesday, July 7th. The stock was sold at an average price of $218.55, for a total transaction of $1,090,783.05. Following the completion of the sale, the chief executive officer directly owned 466,223 shares in the company, valued at $101,893,036.65. This represents a 1.06% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Peter C. Farrell sold 8,000 shares of the stock in a transaction on Wednesday, August 5th. The stock was sold at an average price of $225.00, for a total value of $1,800,000.00. Following the completion of the transaction, the director directly owned 52,773 shares in the company, valued at $11,873,925. This trade represents a 13.16% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 17,982 shares of company stock valued at $3,858,837. Insiders own 0.65% of the company’s stock.

Hedge Funds Weigh In On ResMed

A number of large investors have recently modified their holdings of RMD. BlackRock Inc. acquired a new stake in ResMed during the 2nd quarter worth approximately $2,400,375,000. State Street Corp lifted its position in ResMed by 1.2% during the fourth quarter. State Street Corp now owns 6,625,408 shares of the medical equipment provider’s stock valued at $1,595,862,000 after buying an additional 76,244 shares in the last quarter. Bank of New York Mellon Corp grew its stake in ResMed by 0.7% during the first quarter. Bank of New York Mellon Corp now owns 4,925,386 shares of the medical equipment provider’s stock worth $1,105,651,000 after buying an additional 34,732 shares during the period. Geode Capital Management LLC grew its stake in ResMed by 1.2% during the fourth quarter. Geode Capital Management LLC now owns 4,302,906 shares of the medical equipment provider’s stock worth $1,032,877,000 after buying an additional 51,218 shares during the period. Finally, Morgan Stanley increased its position in shares of ResMed by 25.0% in the fourth quarter. Morgan Stanley now owns 2,891,697 shares of the medical equipment provider’s stock worth $696,523,000 after acquiring an additional 578,559 shares in the last quarter. 54.98% of the stock is currently owned by hedge funds and other institutional investors.

ResMed News Summary

Here are the key news stories impacting ResMed this week:

• Positive Sentiment: ResMed reported fiscal Q4 earnings of $2.95 per share, beating the approximately $2.89–$2.90 consensus and rising from $2.55 a year earlier. Revenue increased 8.6% year over year to $1.46 billion, in line with estimates. ResMed Q4 Earnings and Revenues Top Estimates
• Positive Sentiment: The company raised its quarterly dividend from $0.60 to $0.66 per share, a 10% increase. The dividend is payable September 24 to shareholders of record on August 20, supporting ResMed’s income-investment appeal. ResMed Posts Strong Q4 Earnings and Lifts Dividend
• Positive Sentiment: Royal Bank of Canada raised its price target to $244 from $234 while retaining a “sector perform” rating, indicating potential upside from recent trading levels. Benzinga analyst action
• Neutral Sentiment: Analyst sentiment remains mixed. Piper Sandler lowered its target to $225 and Wells Fargo cut its target to $215; both maintain neutral or equal-weight ratings. The overall analyst consensus remains “Hold,” despite a consensus target near $246. ResMed Analyst Ratings
• Negative Sentiment: The primary pressure on RMD is forward guidance: fiscal 2027 revenue expectations reportedly trail consensus, raising concerns that growth may moderate even after the quarterly earnings beat. RMD Stock Down Despite Q4 Earnings Beat
• Negative Sentiment: Director Peter Farrell sold 8,000 shares worth $1.8 million. The sale was made under a pre-arranged Rule 10b5-1 plan, reducing its negative signaling value, but it may add modest short-term selling pressure. SEC Insider Trading Filing

About ResMed

ResMed (NYSE: RMD) is a global medical device and cloud-connectivity company focused on improving outcomes for people with sleep-disordered breathing and chronic respiratory conditions. Founded in 1989, the company is headquartered in San Diego, California, and develops, manufactures and distributes a range of devices and software used by patients, clinicians and providers worldwide.

ResMed’s product portfolio centers on noninvasive ventilation and sleep therapy equipment, including continuous positive airway pressure (CPAP) and bilevel devices, masks and related accessories for the treatment of obstructive sleep apnea and other respiratory disorders.